Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

ClinicalTrials.gov ID: NCT00619476

Public ClinicalTrials.gov record NCT00619476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Study identification

NCT ID
NCT00619476
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
XenoPort, Inc.
Industry
Enrollment
376 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2008 (Type not available)
Primary completion
Jul 2009 (Actual)
Completion
Jul 2009 (Actual)
Last update posted
Jul 22, 2013

2008 – 2009

United States locations

U.S. sites
72
U.S. states
28
U.S. cities
68
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205 —
GSK Investigational Site Northport Alabama 35476 —
GSK Investigational Site Chandler Arizona 85225 —
GSK Investigational Site Gilbert Arizona 85234 —
GSK Investigational Site Litchfield Park Arizona 85340 —
GSK Investigational Site Scottsdale Arizona 85251 —
GSK Investigational Site Tucson Arizona 85741 —
GSK Investigational Site Little Rock Arkansas 72205 —
GSK Investigational Site Arcadia California 91007 —
GSK Investigational Site Huntington Park California 90255 —
GSK Investigational Site New Port Beach California 92660 —
GSK Investigational Site Northridge California 91325 —
GSK Investigational Site Oxnard California 93030 —
GSK Investigational Site Redondo Beach California 90277 —
GSK Investigational Site Riverside California 92506 —
GSK Investigational Site San Diego California 92117 —
GSK Investigational Site San Francisco California 94109 —
GSK Investigational Site Santa Monica California 90404 —
GSK Investigational Site Boulder Colorado 80304 —
GSK Investigational Site Bradenton Florida 34203 —
GSK Investigational Site Bradenton Florida 34206 —
GSK Investigational Site Daytona Beach Florida 32117 —
GSK Investigational Site Hallandale Florida 33009 —
GSK Investigational Site Hollywood Florida 33021 —
GSK Investigational Site Naranja Florida 33032 —
GSK Investigational Site New Port Richey Florida 34652 —
GSK Investigational Site Ocala Florida 34471 —
GSK Investigational Site St. Petersburg Florida 33702 —
GSK Investigational Site Tallahassee Florida 32308 —
GSK Investigational Site Tampa Florida 33603 —
GSK Investigational Site Tampa Florida 33607 —
GSK Investigational Site Tampa Florida 33612 —
GSK Investigational Site Decatur Georgia 30033 —
GSK Investigational Site Marietta Georgia 30066 —
GSK Investigational Site Chicago Illinois 60611 —
GSK Investigational Site Libertyville Illinois 60048 —
GSK Investigational Site Danville Indiana 46122 —
GSK Investigational Site Elkhart Indiana 46514 —
GSK Investigational Site Terre Haute Indiana 47802 —
GSK Investigational Site Shreveport Louisiana 71101 —
GSK Investigational Site Rockville Maryland 20852 —
GSK Investigational Site Boston Massachusetts 02215 —
GSK Investigational Site Bingham Farms Michigan 48025 —
GSK Investigational Site Olive Branch Mississippi 38654 —
GSK Investigational Site Kansas City Missouri 64111 —
GSK Investigational Site St Louis Missouri 63117 —
GSK Investigational Site Reno Nevada 89502 —
GSK Investigational Site Lebanon New Hampshire 03766 —
GSK Investigational Site Albuquerque New Mexico 87108 —
GSK Investigational Site Amherst New York 14226 —
GSK Investigational Site Brooklyn New York 11235 —
GSK Investigational Site New York New York 10004 —
GSK Investigational Site New York New York 10128 —
GSK Investigational Site Rochester New York 14642 —
GSK Investigational Site Charlotte North Carolina 28204 —
GSK Investigational Site Greensboro North Carolina 27408 —
GSK Investigational Site Hickory North Carolina 28601 —
GSK Investigational Site High Point North Carolina 27262 —
GSK Investigational Site Salisbury North Carolina 28144 —
GSK Investigational Site Winston-Salem North Carolina 27103 —
GSK Investigational Site Cincinnati Ohio 45246 —
GSK Investigational Site Norman Oklahoma 73071 —
GSK Investigational Site Oklahoma City Oklahoma 73112 —
GSK Investigational Site Eugene Oregon 97401 —
GSK Investigational Site Medford Oregon 97501 —
GSK Investigational Site Altoona Pennsylvania 16602 —
GSK Investigational Site San Antonio Texas 78238 —
GSK Investigational Site Weber City Virginia 24290 —
GSK Investigational Site Tacoma Washington 98405 —
GSK Investigational Site Wenatchee Washington 98801 —
GSK Investigational Site Yakima Washington 98902 —
GSK Investigational Site Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00619476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2013 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00619476 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →